Your browser is no longer supported. Please, upgrade your browser.
Settings
RGEN [NASD]
Repligen Corporation
Index- P/E150.53 EPS (ttm)1.78 Insider Own0.70% Shs Outstand54.93M Perf Week6.02%
Market Cap14.84B Forward P/E90.56 EPS next Y2.96 Insider Trans-19.09% Shs Float51.06M Perf Month-14.62%
Income99.90M PEG4.18 EPS next Q0.64 Inst Own86.20% Short Float3.29% Perf Quarter30.21%
Sales508.50M P/S29.18 EPS this Y155.50% Inst Trans0.16% Short Ratio4.46 Perf Half Y24.01%
Book/sh29.18 P/B9.19 EPS next Y11.40% ROA5.50% Target Price257.88 Perf Year55.52%
Cash/sh13.27 P/C20.21 EPS next 5Y36.00% ROE6.90% 52W Range162.29 - 327.32 Perf YTD39.98%
Dividend- P/FCF336.50 EPS past 5Y31.90% ROI4.00% 52W High-17.28% Beta0.83
Dividend %- Quick Ratio2.60 Sales past 5Y34.40% Gross Margin58.80% 52W Low66.84% ATR10.13
Employees1128 Current Ratio3.00 Sales Q/Q86.30% Oper. Margin24.20% RSI (14)47.90 Volatility3.14% 3.79%
OptionableYes Debt/Eq0.16 EPS Q/Q114.40% Profit Margin19.70% Rel Volume0.67 Prev Close268.25
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout0.00% Avg Volume376.04K Price270.76
Recom1.70 SMA20-2.03% SMA50-3.11% SMA20021.76% Volume250,074 Change0.94%
Oct-14-21Initiated Exane BNP Paribas Outperform $330
Nov-10-20Initiated KeyBanc Capital Markets Overweight $241
Aug-24-20Reiterated H.C. Wainwright Buy $151 → $168
Jun-30-20Reiterated H.C. Wainwright Buy $143 → $151
May-07-20Reiterated H.C. Wainwright Buy $100 → $143
Mar-23-20Reiterated H.C. Wainwright Buy $110 → $100
Nov-15-19Initiated Stifel Buy
Nov-01-19Upgrade First Analysis Sec Outperform → Strong Buy $107 → $110
Oct-15-19Initiated SVB Leerink Outperform $100
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Oct-18-21 06:45AM  
Oct-14-21 07:30AM  
Oct-12-21 11:45AM  
Oct-06-21 07:59AM  
Sep-29-21 11:27AM  
Sep-22-21 11:40AM  
07:27AM  
Sep-21-21 09:34AM  
Sep-16-21 01:08PM  
07:40AM  
Sep-14-21 11:27AM  
Sep-09-21 07:30AM  
Sep-03-21 10:10AM  
Aug-30-21 11:02AM  
Aug-26-21 11:31AM  
Aug-23-21 09:56AM  
Aug-20-21 09:01AM  
Aug-19-21 10:47AM  
07:00AM  
Aug-18-21 10:05AM  
Aug-17-21 08:37AM  
Aug-12-21 11:40AM  
Aug-11-21 12:45PM  
Aug-10-21 10:54AM  
Aug-09-21 10:33AM  
Aug-06-21 11:26AM  
Aug-05-21 11:42AM  
Aug-04-21 12:20PM  
Aug-03-21 09:33AM  
Jul-30-21 12:10PM  
11:23AM  
06:11AM  
Jul-28-21 10:00AM  
09:35AM  
Jul-27-21 02:00PM  
08:45AM  
07:30AM  
Jul-22-21 06:15AM  
Jul-20-21 03:02PM  
Jul-19-21 11:32AM  
Jul-16-21 01:54PM  
Jul-15-21 01:43PM  
Jul-13-21 10:21AM  
07:30AM  
Jul-09-21 05:45AM  
Jul-08-21 11:23AM  
Jul-06-21 08:50AM  
Jul-05-21 05:28AM  
Jul-02-21 11:01AM  
Jul-01-21 10:32AM  
Jun-30-21 11:08AM  
Jun-29-21 11:15AM  
Jun-28-21 11:18AM  
08:29AM  
Jun-24-21 12:38PM  
Jun-22-21 07:20AM  
Jun-21-21 05:05PM  
Jun-18-21 11:08AM  
03:00AM  
Jun-16-21 11:49AM  
08:00AM  
Jun-11-21 12:38PM  
10:42AM  
Jun-10-21 12:12PM  
Jun-09-21 10:28AM  
10:03AM  
Jun-08-21 06:08AM  
Jun-03-21 11:31AM  
Jun-02-21 11:02AM  
08:16AM  
May-31-21 05:16PM  
May-27-21 03:08PM  
May-25-21 07:30AM  
May-24-21 03:36PM  
07:52AM  
May-21-21 08:46AM  
May-20-21 10:14AM  
10:02AM  
09:29AM  
09:26AM  
May-19-21 10:38AM  
08:47AM  
May-18-21 05:27PM  
May-17-21 06:29AM  
May-14-21 02:04PM  
May-12-21 03:32PM  
May-11-21 11:30AM  
11:21AM  
May-10-21 07:35AM  
May-09-21 04:33AM  
May-07-21 12:17PM  
08:58AM  
08:52AM  
May-04-21 04:18PM  
02:00PM  
12:20PM  
08:45AM  
07:30AM  
06:45AM  
Apr-30-21 10:28AM  
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAWES KAREN ADirectorSep 14Sale294.2627480,62893,647Sep 15 05:46 PM
Hunt AnthonyChief Executive OfficerSep 09Option Exercise32.4025,000810,000214,495Sep 13 06:24 PM
Hunt AnthonyChief Executive OfficerSep 09Sale294.7525,0007,368,650189,495Sep 13 06:24 PM
Gebski ChristineSee RemarksSep 01Sale285.333,377963,55933,318Sep 02 04:33 PM
DAWES KAREN ADirectorSep 01Sale283.913,459982,05893,921Sep 02 04:29 PM
KURIYEL RALFSenior VP, R&DAug 30Sale282.134,0011,128,80217,354Sep 02 06:54 AM
DAWES KAREN ADirectorAug 18Sale259.031,402363,16693,961Aug 19 04:42 PM
DAWES KAREN ADirectorAug 17Sale253.7717,5144,444,56195,363Aug 19 04:42 PM
RYAN THOMAS F JRDirectorAug 04Sale250.50780195,390971Aug 05 07:33 PM
DAWES KAREN ADirectorJul 20Sale202.094,585926,605112,877Jul 22 08:25 PM
DAWES KAREN ADirectorJul 13Option Exercise41.192,929120,646118,982Jul 15 05:17 PM
KURIYEL RALFSenior VP, R&DJun 10Option Exercise67.233,602242,16728,157Jun 14 06:48 PM
KURIYEL RALFSenior VP, R&DJun 10Sale189.196,8021,286,87021,355Jun 14 06:48 PM
Hunt AnthonyChief Executive OfficerMay 19Sale171.4122,2673,816,698190,495May 20 09:00 PM
Gebski ChristineSee RemarksMay 14Sale172.2544576,65136,695May 18 07:52 AM
KURIYEL RALFSenior VP, R&DMay 14Sale172.29710122,32624,555May 18 07:50 AM
Snodgres JonChief Financial OfficerMay 14Sale172.6047081,12231,893May 18 07:49 AM
DAWES KAREN ADirectorMay 11Option Exercise3.2215,00048,300115,734May 13 05:01 PM
DAWES KAREN ADirectorMay 11Sale176.8528550,402115,449May 13 05:01 PM
Bylund JamesSVP, Global Operations & ITApr 06Sale204.2536073,5306,324Apr 08 07:55 PM
Gebski ChristineSee RemarksMar 16Sale196.881,400275,63237,140Mar 18 09:47 PM
Hunt AnthonyChief Executive OfficerMar 12Sale190.389,1021,732,847212,762Mar 12 07:34 PM
KURIYEL RALFSenior VP, R&DMar 10Option Exercise34.158,000273,16833,265Mar 12 07:33 PM
KURIYEL RALFSenior VP, R&DMar 10Sale190.448,0001,523,50125,265Mar 12 07:33 PM
Hunt AnthonyChief Executive OfficerMar 04Sale190.1921,9004,165,091221,864Mar 08 09:51 PM
Snodgres JonChief Financial OfficerMar 04Sale192.473,545682,29532,363Mar 08 09:50 PM
KURIYEL RALFSenior VP, R&DMar 04Sale192.002,075398,39625,265Mar 08 09:41 PM
RYAN THOMAS F JRDirectorMar 03Option Exercise26.121,00026,1202,464Mar 04 09:22 PM
RYAN THOMAS F JRDirectorMar 03Sale205.001,000205,0001,464Mar 04 09:22 PM
Snodgres JonChief Financial OfficerJan 25Option Exercise33.874,000135,48033,498Jan 26 09:59 PM
Snodgres JonChief Financial OfficerJan 04Sale191.523,957757,84029,498Jan 06 04:41 PM
KURIYEL RALFSenior VP, R&DDec 16Sale186.1843580,98825,654Dec 18 04:30 PM
Hunt AnthonyChief Executive OfficerNov 19Option Exercise26.0520,000521,000253,327Nov 23 07:03 PM
Hunt AnthonyChief Executive OfficerNov 19Sale185.8020,0003,716,051233,327Nov 23 07:03 PM
RYAN THOMAS F JRDirectorNov 11Option Exercise38.7693436,2022,398Nov 13 04:46 PM
RYAN THOMAS F JRDirectorNov 11Sale187.73934175,3401,464Nov 13 04:46 PM
Snodgres JonChief Financial OfficerNov 10Option Exercise32.403,08699,98636,541Nov 10 09:17 PM
Snodgres JonChief Financial OfficerNov 10Sale193.003,086595,59833,455Nov 10 09:17 PM
Snodgres JonChief Financial OfficerNov 09Option Exercise59.521,893112,67133,455Nov 10 09:17 PM
BARTHELEMY NICOLASDirectorNov 09Sale195.511,214237,3491,450Nov 10 09:18 PM
Snodgres JonChief Financial OfficerNov 09Sale194.69705137,25631,562Nov 10 09:17 PM